The purpose of this research is to understand how to apply cardiac magnetic resonance
imaging (CMR) to women with small artery heart disease by looking at the CMRs of women
without heart disease. The investigators will study 40 women with no heart disease to learn
more about the usefulness of CMR.
Women suffer more than men from this disorder of the small vessels compared to the large
vessels. This results in delays in diagnosis, missed opportunities for treatment, and likely
contributes to the increased death rate from heart disease in women compared to men. Current
testing for small vessel disease is invasive and not performed routinely and women are often
not initiated on appropriate lifesaving treatment. New imaging and noninvasive technology
exists that may improve this situation. Imaging techniques such as cardiac magnetic
resonance imaging (CMR) can now show the inner layers of the heart where the small vessel
abnormality and myocardial ischemia exist. These techniques, while promising, have not been
tested to determine if they can be used to diagnose and treat the small vessel coronary
heart disease condition. They also have not been studied extensively in women without heart
Gadolinium, the contrast agent that will be given Intravenously to all study participants
during the cardiac MRI procedure, is contraindicated to patients with renal impairment. Even
though it will only be given once to each of our patients, the investigators still wanted to
establish the fact that these study participants have "normal" or good renal functioning by
doing BUN and Creatinine blood tests prior to the administration of this contrast agent to
their system. By adding these lab tests, the investigators will be more cautious to the
well-being and safety of the study participants.
The investigators will be recruiting women aged 35-65 years with no known heart disease or
heart disease risk factors like high blood pressure or high cholesterol. Participants will
discuss the cardiac magnetic resonance procedure with a research doctor and if they agree,
will fill out questionnaires related to their health, have blood draw and then undergo the
CMR procedure. This can be completed in 1 or 2 visits. No follow up is needed.
The women will be consented and enrolled. They will:
1. fill out baseline demographic and health history questionnaires;
2. have an exercise treadmill test (ETT) To rule out any underlying ischemic heart
3. undergo rest-stress CMR testing (up to 3 scans);
4. peripheral arterial tonometry; and
5. have blood drawn for hematocrit, blood urea nitrogen (BUN),creatinine, and research
protein quantitation with mass spectrometry and enzyme-linked immunosorbent assay
(ELISA) for sensitive quantitation of cardiovascular biomarkers.
1. Women without signs and symptoms of myocardial ischemia (chest pain, abnormal stress
testing, abnormal noninvasive testing).
2. No cardiac risk factors by Framingham/NCEP criteria, age and BMI matched to the
Cardiac Syndrome X population, and a normal exercise stress test.
1. Contraindications to CMR testing (metal devices in chest, claustrophobia, known
2. Contraindication to Adenosine or Lexiscan (regadenoson) including heart block (second
and third degree) and sinus node disease, significant COPD/asthma, or systemic
hypotension (<90 mmHg).
3. Contraindication to Dobutamine including severe systemic hypertension (≥ 220/120
mmHg), unstable angina, significant aortic valve stenosis, complex cardiac arrhythmia
including uncontrolled atrial fibrillation, hypertrophic obstructive cardiomyopathy,
myocarditis, endocarditis, pericarditis, or uncontrolled congestive heart failure.
4. Contraindication to Gadolinium (renal impairment).
5. Any renal disease.
6. Pregnant and lactating women.
7. Inability to perform exercise, eg. orthopedic limitations.
8. Allergy to animal dander.